Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced it will report its fourth quarter and full year 2024 financial results on Thursday, February 13, 2025, before U.S. markets open. The company's management will host a conference call at 8:30 am ET on the same day to discuss the results and provide updates on the company's operations and future outlook.
A live audio webcast will be available on the Investors section of Alnylam's website, with an archived version accessible approximately two hours after the event.
Alnylam Pharmaceuticals (Nasdaq: ALNY) ha annunciato che riporterà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 giovedì 13 febbraio 2025, prima dell'apertura dei mercati statunitensi. Il management dell'azienda ospiterà una conferenza telefonica alle 8:30 ET lo stesso giorno per discutere i risultati e fornire aggiornamenti sulle operazioni aziendali e le prospettive future.
Una webconferenza audio in diretta sarà disponibile nella sezione Investitori del sito web di Alnylam, con una versione archiviata accessibile circa due ore dopo l'evento.
Alnylam Pharmaceuticals (Nasdaq: ALNY) ha anunciado que informará sus resultados financieros del cuarto trimestre y del año completo 2024 el jueves 13 de febrero de 2025, antes de la apertura de los mercados en EE. UU. La dirección de la empresa llevará a cabo una conferencia telefónica a las 8:30 a.m. ET el mismo día para discutir los resultados y ofrecer actualizaciones sobre las operaciones de la empresa y las perspectivas futuras.
Se dispondrá de una transmisión de audio en vivo en la sección de Inversores del sitio web de Alnylam, con una versión archivada accesible aproximadamente dos horas después del evento.
Alnylam Pharmaceuticals (Nasdaq: ALNY)는 2024년 4분기 및 연간 재무 결과를 2025년 2월 13일 목요일, 미국 시장이 열리기 전에 발표할 것이라고 발표했습니다. 회사 경영진은 같은 날 오전 8시 30분(ET)에 결과를 논의하고 회사 운영 및 향후 전망에 대한 업데이트를 제공하기 위해 전화 회의를 개최합니다.
Alnylam 웹사이트의 투자자 섹션에서는 실시간 오디오 웹캐스트가 제공되며, 이벤트 후 약 2시간 후에 아카이브된 버전이 액세스 가능합니다.
Alnylam Pharmaceuticals (Nasdaq: ALNY) a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année 2024 le jeudi 13 février 2025, avant l'ouverture des marchés aux États-Unis. La direction de l'entreprise organisera une conférence téléphonique à 8h30 ET le même jour pour discuter des résultats et fournir des mises à jour sur les opérations de l'entreprise et les perspectives d'avenir.
Un webinaire audio en direct sera disponible dans la section Investisseurs du site web d'Alnylam, avec une version archivée accessible environ deux heures après l'événement.
Alnylam Pharmaceuticals (Nasdaq: ALNY) hat angekündigt, dass es am Donnerstag, den 13. Februar 2025, vor der Eröffnung der US-Märkte seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 bekannt geben wird. Das Management des Unternehmens wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Updates zu den Unternehmensabläufen und zukünftigen Perspektiven zu geben.
Ein Live-Audio-Webcast wird im Investorensegment der Alnylam-Website verfügbar sein, und eine archivierte Version wird etwa zwei Stunden nach der Veranstaltung zugänglich sein.
- None.
- None.
Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250130029623/en/
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
FAQ
When will Alnylam (ALNY) release Q4 and full-year 2024 earnings?
What time is Alnylam's (ALNY) Q4 2024 earnings call?
How can investors access Alnylam's (ALNY) Q4 2024 earnings call?
Will Alnylam's (ALNY) Q4 2024 earnings call be available for replay?
